Lung cancer and CYP1A1 or GSTM1 polymorphisms

Environmental Health and Preventive Medicine

Volumn 7, Issue 6, 2003, Pages 230-234

  Oyama, Tsunehiro ^a   Kagawa, Norio ^b   Kim, Yong Dae ^a   Matsumoto, Akiko ^a   Isse, Toyohi ^a   Kawamoto, Toshihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome p4501A1 gene (CYP1A1) polymorphism; Glutathione S transferase gene (GSTM1) polymorphism; Non small cell lung cancer (NSCLC); p53 gene mutation; Survival curve

Indexed keywords

CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE; PROTEIN P53;

CANCER SURVIVAL; CANCER SUSCEPTIBILITY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; REVIEW;

EID: 0037273155     PISSN: 1342078X     EISSN: None     Source Type: Journal    
DOI: 10.1265/ehpm.2003.230     Document Type: Review

References (20)

1. Kinzler KW, Vagelstein B. Gatekeepers and caretakers. Nature 1997; 386: 761-763.
2. Vineis P, Porta M. Casual thinking, biomarkers, and mechanisms of carcinogenesis. J. Clin. Epidemiol. 1996; 49: 951-956.
3. Harris CC. Interindividual variation among humans in carcinogen metabolism, DNA adduct formation and DNA repair. Carcinogenesis 1989; 10: 1563-1566.
4. Bouchardy C, Benhamou S, Jourenkova N, Dayer P, Hirvonen A. Metabolic genetic polymorphisms and susceptibility to lung cancer. Lung Cancer 2001; 32: 109-112.
5. Lai C, Shields PG. The role of interindividual variation in human carcinogenesis. J. Nutr. 1999; 129: 552s-555s.
6. Hayashi S-I, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J. Biochem. 1991; 110: 407-411.
7. Eaton DL, Bammler TK. Concise review of the glutathione Stransferases and their significance to toxicology. Toxicol. Sci. 1999; 49: 156-164.
8. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione Stransferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J. Biol. Chem. 1997; 272: 10004-10012.
9. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 275-280.
10. Nakachi K, Imai K, Hayashi S-I, Kawajiri K. Polymorphisms of the CYP1A1 and Glutathione S-Transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993; 53: 2994-2999.
11. d'Errico A, Malats N, Vineis P, Boffetta P. Chapter 23. Review of studies of selected metabolic polymorphisms and cancer. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J and Boffetta P (eds.) Metabolic polymorphisms and susceptibility to cancer. Lyon; International Agency for Research on Cancer, 1999: 323-393.
12. Oyama T, Kawamoto T, Mizoue T, Nishida K, Osaki T, Sugio K, Yasumoto K, Mitsudomi T. p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int. J. Oncol. 1997; 11: 305-309.
13. Suzuki H, Takashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 1992; 52: 734-736.
14. Strauss BS. The origine of point mutations in human tumor cells. Cancer Res. 1992; 52: 242-253.
15. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowits S, Willson JKV, Hamilton S, Vogelstein B. p53 mutations occur in combination with 17p allelic delations as late events in colorectal tumorigenesis. Cancer Res. 1990; 50: 7717-7722.
16. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst. 1993; 85: 2018-2023.
17. Korkolopoulou P, Oates J, Crocker J, Edwards C. p53 expression in oat and non-oat small cell lung carcinomas: correlations with proliferating cell nuclear antigen. J. Clin. Pathol. 1993; 46: 1093-1096.
18. Ebina M, Steinberg SM, Mulshine JL, Linnolia RI. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994; 54: 2496-2503.
19. Tormanen U, Eerola AK, Rainio P, Vahakangas K, Soini Y, Sormunen R, Bloigue R, Lehto VP, Paakko P. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res. 1995; 55: 5595-5602.
20. Esposito V, Baldi A, De Luca A, Micheli P, Mazzarella G, Baldi F, Caputi M, Giordano A. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol. 1997; 28: 233-237.